You just read:

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy

News provided by

Jazz Pharmaceuticals plc

Mar 15, 2017, 16:05 ET